CD274 and neoplasm: Biomarkers such as programmed cell death-ligand 1 combined positive score (PD-L1 CPS)5, microsatellite instability (MSI) 6, and tumor mutational burden (TMB)7, approved by the Food and Drug Administration (FDA) for predicting immunotherapy outcomes, have been validated in multiple clinical studies.